Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: A prospective, randomized study | Zendy

Deepankur Mahajan | Zendy; Rajvardhan Azad | Zendy; Siddarth Sain | Zendy; Yog Raj Sharma | Zendy

Open Access

Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: A prospective, randomized study

Author(s) -

Deepankur Mahajan,

Rajvardhan Azad,

Siddarth Sain,

Yog Raj Sharma

Publication year - 2012

Publication title -

oman journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.306

H-Index - 16

eISSN - 0974-7842

pISSN - 0974-620X

DOI - 10.4103/0974-620x.106100

Subject(s) - medicine , acetonide , triamcinolone acetonide , ophthalmology , refractory (planetary science) , diabetic macular edema , macular edema , visual acuity , bevacizumab , intraocular pressure , randomized controlled trial , diabetic retinopathy , surgery , diabetes mellitus , chemotherapy , physics , astrobiology , endocrinology

In spite of laser being the gold standard treatment for Diabetic Macular edema (DME), some patients do not respond to laser. Various treatment modalities are being tried in the management of refractory diffuse DME (DDME).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research